Protagenic Therapeutics, Inc. Warrant
PTIXW
About: Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Employees: 3
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
157% more capital invested
Capital invested by funds: $2.63K [Q1] → $6.76K (+$4.13K) [Q2]
3.37% less ownership
Funds ownership: 7.67% [Q1] → 4.3% (-3.37%) [Q2]
33% less funds holding
Funds holding: 6 [Q1] → 4 (-2) [Q2]
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Financial journalist opinion
We haven’t received any recent news articles for PTIXW